🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "huge turning point" in the effort against drug-resistant strains of the infection, according to researchers.

A Global Challenge

The sexually transmitted infection are increasing globally, with estimates suggesting over 82 million instances each year. Notably increased rates are reported in Africa and countries within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune step in the reality of increasing worldwide cases, escalating drug resistance and the extremely scarce treatment choices at this time.”

Public health authorities are particularly alarmed about the surge in treatment-resistant strains. The World Health Organization has designated it as a "high-priority threat". Ongoing monitoring revealed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Drugs Gain Approval

One new antibiotic, alternatively called Nuzolvence, was cleared by the US FDA in recent days for combating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Researchers hope that targeted use of this new drug will help slow the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This treatment, which is additionally indicated for UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin emerged from a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This authorization represents a huge turning point in the treatment of superbug gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Testing Data and Global Access

According to results published in a major medical journal, the new drug cured the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the existing first-line therapy, which uses a dual-drug approach. The research enrolled hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the authority to register and commercialise the drug in a wide range of low-income and middle-income countries.

Doctors directly involved have shared positive views. The availability of a one-pill regimen of this kind is seen as a "revolutionary step" for managing the epidemic. This is deemed vital to lessen the impact of the illness for people and to prevent the spread of highly drug-resistant gonorrhoea around the world.